FindTrial
Sign In

Study of cancer related outcomes for patients with advanced breast cancer undergoing breast preserving surgery after receiving chemotherapy.

Oncological outcomes of breast conservation surgery in patients with locally advanced breast cancer post neoadjuvant chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/12/016544
Enrollment
75
Registered
2018-12-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

None listed

Sponsors

Department of Surgical Disciplines
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All female patients registered under Surgery Unit III breast cancer clinic with: 1. Locally advanced breast cancer and primary tumor size greater than or equal to 5cm suitable for undergoing breast conservation surgery post neoadjuvant chemotherapy. 2. Patient giving consent. 3. Minimum follow up of 6 months.

Exclusion criteria

Exclusion criteria: Breast cancer patients: 1. Having Chest wall fixation (T4a) 2. Having satellite nodules 3. Having inflammatory Carcinoma (T4d) 4. With Stages not included in the inclusion criteria. 5. Who are Pregnant, Lactating 6. Having contraindication to Radiotherapy. 7. With multicentric disease. 8. With diffuse microcalcifications on mammography. 9. Not giving consent. 10. With incomplete records. 11. Lost to follow up.

Design outcomes

Secondary

MeasureTime frame
1. To ascertain the disease free survival (DFS) and overall survival (OS) in these patients. 2. To study the factors associated with increased risk of ipsilateral breast tumor recurrence Timepoint: 31st March 2020—

Primary

MeasureTime frame
To study the ipsilateral breast tumor recurrence (IBTR) in patients with Locally advanced breast cancer undergoing Breast conservation surgery post neoadjuvant chemotherapy.Timepoint: 31st March 2020—

Countries

India

Contacts

Public ContactDr Priyank Bhargava

AIIMS,New delhi

drsuhani@gmail.com9868397697

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026